Literature DB >> 23245476

The heart: pathophysiology and clinical implications of cirrhotic cardiomyopathy.

Ying-Ying Yang1, Han-Chieh Lin.   

Abstract

Cirrhosis is associated with hyperdynamic circulation, which consists of peripheral vasodilatation and increased cardiac output. Peripheral vasodilatation is central to hyperdynamic circulation and portal hypertension in cirrhosis. However, those mechanisms underlying hyperdynamic circulation remain elusive, and are not fully understood. Most of the earlier research and attention have been focused on humoral factor abnormalities. Various gut-derived or locally produced humoral factors such as nitric oxide, endotoxin, endocannabinoids, and others have been implicated as possible mediators of hyperdynamic circulation development in cirrhosis. The associated cardiac dysfunction had been termed "cirrhotic cardiomyopathy (CCM)," which is an entity different from that seen in alcoholic heart muscle disease. Clinically, these patients present with sodium fluid retention, and strain often unmasks the presence of latent heart failure. No specific treatment can yet be recommended, but caution should be used with respect to procedures that may stress the heart such as shunt implantation and liver transplantation. Ultimately, additional research will be necessary to more accurately describe the prevalence, impact, and morbidity and survival rates for CCM, and to identify potential treatments.
Copyright © 2012. Published by Elsevier B.V.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23245476     DOI: 10.1016/j.jcma.2012.08.015

Source DB:  PubMed          Journal:  J Chin Med Assoc        ISSN: 1726-4901            Impact factor:   2.743


  7 in total

Review 1.  Arrhythmia risk in liver cirrhosis.

Authors:  Ioana Mozos
Journal:  World J Hepatol       Date:  2015-04-08

2.  Left Ventricular Diastolic Dysfunction is Associated with Renal Dysfunction, Poor Survival and Low Health Related Quality of Life in Cirrhosis.

Authors:  Madhumita Premkumar; Devaraja Devurgowda; Tanmay Vyas; Saggere M Shasthry; Jelen S Khumuckham; Ritu Goyal; Sherin S Thomas; Guresh Kumar
Journal:  J Clin Exp Hepatol       Date:  2018-08-30

3.  Cirrhotic Cardiomyopathy: Another Case of a Successful Approach to Treatment of Hepatorenal Syndrome.

Authors:  Luis Otávio Mocarzel; Jessica Bicca; Luiza Jarske; Thamires Oliveira; Pedro Lanzieri; Ronaldo Gismondi; Mario Luiz Ribeiro
Journal:  Case Rep Gastroenterol       Date:  2016-10-10

4.  Cardiac health in patients with hepatitis B virus-related cirrhosis.

Authors:  Wei Yuan; Hong-Zhou Lu; Xue Mei; Yu-Yi Zhang; Zheng-Guo Zhang; Ying Zou; Jie-Fei Wang; Zhi-Ping Qian; Hong-Ying Guo
Journal:  Medicine (Baltimore)       Date:  2019-03       Impact factor: 1.889

5.  Risk Factors of Atrial Arrhythmia in Patients With Liver Cirrhosis: A Retrospective Study.

Authors:  Xiya Lu; Zhijing Wang; Liu Yang; Changqing Yang; Meiyi Song
Journal:  Front Cardiovasc Med       Date:  2021-07-05

6.  SHSST cyclodextrin complex prevents the fibrosis effect on CCl₄-induced cirrhotic cardiomyopathy in rats through TGF-β pathway inhibition effects.

Authors:  Cheng-Hsun Yang; Wei-Jen Ting; Cecilia Hsuan Day; Da-Tong Ju; Yu-Lan Yeh; Li-Chin Chung; Fu-Jenn Tsai; Chang-Hai Tsai; Yuhsin Tsai; Chih-Yang Huang
Journal:  Int J Mol Sci       Date:  2014-05-08       Impact factor: 5.923

7.  Myocardial Performance after Successful Liver Transplantation.

Authors:  H Amoozgar; R Ermis; N Honar; S A Malek-Hosseini
Journal:  Int J Organ Transplant Med       Date:  2016-05-01
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.